VivoSeq
Nephrology

Alport Syndrome

17

Pipeline Programs↗

5

Active Trials↗

15

Companies Involved↗

Alport syndrome is an emerging landscape with 17 programs across 15 companies. The most active players are Mario Negri Institute for Pharmacological Research, Bayer, Enyo Pharma. 3 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

6/100

Mech. Concentration

14/100

Completion Rate

89/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

2 programs

Phase 2Bayer logo

Bayer

1 program

Phase 2E

Enyo Pharma

1 program

Phase 2E

Eloxx Pharmaceuticals, Inc.

1 program

Phase 2C

Calliditas Therapeutics Suisse SA

1 program

Phase 2Sanofi logo

Sanofi

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

95%

Small molecule

19 of 20 classified programs — the dominant modality here.

5%ALL OTHERSCell therapy15%

Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 87% of 23 pipeline programs.

Analysis

Trial Status

15

clinical trials

Completed8 · 53%
Not yet recruiting2 · 13%
Recruiting2 · 13%
Active, not recruiting1 · 7%
Terminated1 · 7%
Unknown status1 · 7%

Clinical Trials

Trial Activity

15 trials

Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
Recruiting·UUniversity Hospital Goettingen·N/A·NCT02378805·800 enrolled
A Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 2a Study With an Extension Phase to Evaluate the Efficacy and Safety of BAY 3401016 in Participants Aged 18 to 45 With Alport Syndrome
Recruiting·Bayer logoBayer·Phase 2·NCT07211685·60 enrolled
Effects of Dapagliflozin on Progression of Alport Syndrome
Active, not recruiting·NNanjing University School of Medicine·N/A·NCT06226896·222 enrolled
Human Umbilical Cord Mesenchymal Stem Cells for Alport Syndrome
Not yet recruiting·GGuangzhou Women and Children's Medical Center·Phase 2/3·NCT06731192·40 enrolled
Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants
Not yet recruiting·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT05133050·510 enrolled
Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome
Completed·IInstitut fuer anwendungsorientierte Forschung und klinische Studien GmbH·Phase 3·NCT01485978·66 enrolled
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
Completed·Biogen logoBiogen·Phase 2/3·NCT03019185·187 enrolled
Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)
Completed·EEnyo Pharma·Phase 2·NCT06425055·26 enrolled
Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome
Completed·Mario Negri Institute for Pharmacological Research logoMario Negri Institute for Pharmacological Research·Phase 2·NCT00309257·9 enrolled
A Study of ELX-02 in Patients With Alport Syndrome
Completed·EEloxx Pharmaceuticals, Inc.·Phase 2·NCT05448755·3 enrolled
A Study of RG-012 in Subjects With Alport Syndrome
Completed·Sanofi logoSanofi·Phase 1·NCT03373786·4 enrolled
A Study to Evaluate Setanaxib in Patients With Alport Syndrome
Completed·CCalliditas Therapeutics AB·Phase 1/2·NCT06274489·20 enrolled
A Unicentric, Randomized, Open-label, Cross-over Clinical Trial to Assess the Effect of Dapagliflozin, Spironolactone and Their Combination, When Added to Renin-Angiotensin System Blockade, On Lowering Urine Albumin-to-Creatinine Ratio in Adult Patients With Alport Syndrome
Completed·—·Approved·NCT06499948·12 enrolled
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome
Terminated·Sanofi logoSanofi·Phase 2·NCT02855268·43 enrolled
Treatment With Metformin in Chinese Children With Alport Syndrome
Unknown status·PPeking University First Hospital·Phase 4·NCT05655728·78 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)